Clinical DevelopmentThe Phase 1 trial investigating TH103, a long-acting anti-VEGF agent, for neovascular age-related macular degeneration is progressing as planned.
Financial PositionThe company ended the first quarter of 2025 with $101 million in cash, providing a financial runway for future developments.
Market PotentialThe global branded anti-VEGF market is still worth more than $15 billion and is growing at a steady pace, illustrating the potential value of a therapy that meaningfully extends treatment intervals.